Key Highlights

  • Revenue rose 13% to A$10,867 million for the year to 30 June 2026.
  • Underlying EBITDA rose 11% to A$1,933 million.
  • FY27 underlying EBITDA guidance of A$1,950 million to A$2,030 million implies much slower growth.
  • Growth has been driven by acquisitions, with consolidation of laboratories and purchasing a recurring source of efficiency.

What does Sonic Healthcare Limited's (ASX:SHL) FY26 result tell us about its growth, and why is the FY27 guidance more modest? The pathology and diagnostics group reported on 20 August 2026 that Revenue rose 13% to A$10,867 million for the year to 30 June 2026, with underlying EBITDA up 11% to A$1,933 million. But FY27 underlying EBITDA guidance of A$1,950 million to A$2,030 million implies much slower growth, and it is in that gap, between acquisition-driven expansion and organic momentum, that the Investment debate sits.

What Sonic does

Sonic is a global medical diagnostics company. Its core is clinical pathology (laboratory testing ordered by doctors), supplemented by radiology and other medical services in several countries. Revenue arises from testing volumes and the prices or fees paid by government health programs, insurers and patients, so Earnings depend on testing activity, reimbursement settings and laboratory efficiency. Scale is an advantage, because laboratory networks have high fixed costs and benefit from volume. Efficiency gains from consolidating laboratories and purchasing are therefore a recurring theme in its results. The company has historically expanded through acquisitions, which gives it exposure to a range of countries and regulatory regimes.

The FY26 numbers

Revenue of A$10,867 million, up 13%, with organic growth of 5%.

Underlying EBITDA of A$1,933 million, up 11%.

Underlying NPAT of A$621 million, up 17%.

Earnings per share of 125.6 cents, up 14%.

Total dividends of A$1.08 per share, including a final Dividend of A$0.63 franked to 60%.

The gap between 13% revenue growth and 5% organic growth is explained by acquisitions: the German provider LADR and Cairo Diagnostics were acquired during FY26.

Integration and balance sheet

A sale and leaseback converts an owned asset into cash but adds ongoing Lease obligations, so it improves Leverage metrics while leaving a continuing cost.

The company has also flagged about A$30 million a year over the next three years to modernise finance, Supply chain and HR systems. That spending is excluded from the FY27 underlying EBITDA guidance, so reported earnings may be lower than the guided figure.

FY27 guidance in context

Sonic guides FY27 underlying EBITDA of A$1,950 million to A$2,030 million at constant currency, excluding IT transformation program costs.

Management cited two headwinds: regulatory changes in Switzerland and a slower ramp-up of profit from the UK NHS contract. These are specific, identifiable issues rather than a general slowdown, which allows investors to monitor them. Pathology in Europe is sensitive to government reimbursement decisions, so changes in a single country's fee schedule can affect earnings. Contract ramp-ups are also uneven, as new work requires investment in capacity before profits appear.

Competitive and sector position

In Australia, Sonic competes with Healius and Australian Clinical Labs in pathology and with other imaging providers in radiology. Internationally it competes with large laboratory groups and with hospital-based laboratories. Its advantages include scale, a diversified geographic footprint and relationships with doctors and health systems. Its weaknesses include exposure to government-set pricing, labour cost Inflation and the Demand for ongoing investment in technology.

Risks to monitor

Key risks include changes to reimbursement in Switzerland, Germany, the United Kingdom and Australia; slower-than-expected profit from the UK NHS contract; integration risk on acquisitions; currency movements, since a large share of earnings is generated outside Australia; wage inflation; and the cost and execution risk of the IT transformation. A cyber incident or major laboratory systems failure is also a generic risk for any diagnostics business, given the sensitivity of patient data.

What to watch

Upcoming developments include the first-half FY27 result and whether the company holds to its A$1,950 million to A$2,030 million range; evidence of the Swiss regulatory impact in practice; the pace of the UK NHS contract ramp; further synergies from LADR; the treatment of IT transformation costs in reported earnings; and any further acquisitions. Because growth in FY26 was partly purchased, organic growth relative to the 5% reported in FY26 is a useful indicator of the underlying health of the business.